about-banner

Fmoc PNA Monomers

Fmoc PNA Monomers

Creative Peptides provides a full range of peptide nucleic acid (PNA) products and related services. Click here to learn about PNA monomers prepared by Fmoc for the synthesis of PNA oligomers.

Browse our catalog below to find your products of interest.

Structure Product Name / CAS / Cat Description / Size Price
Fmoc-A(Bhoc)-Aeg-OH
CAS:186046-82-2
Catalog:FM-001
PNA monomer incorporating a A nucleobase analogue through the Fmoc protecting group
Formula:C40H35N7O7
Formula Weight:725.75
Size:1 g/2 g/ 5 g/10 g/25 g
Fmoc-C(Bhoc)-Aeg-OH
CAS:186046-81-1
Catalog:FM-002
PNA monomer incorporating a C nucleobase analogue through the Fmoc protecting group
Formula:C39H35N5O8
Formula Weight:701.72
Size:1 g/2 g/ 5 g/10 g/25 g
Fmoc-G(Bhoc)-Aeg-OH
CAS:186046-83-3
Catalog:FM-003
PNA monomer incorporating a G nucleobase analogue through the Fmoc protecting group
Formula:C40H35N7O8
Formula Weight:741.75
Size:1 g/2 g/ 5 g/10 g/25 g
Fmoc-J-(Boc)-Aeg-OH
CAS:1095275-70-9
Catalog:FM-004

Formula:C30H33N5O8
Formula Weight:591.61
Size:1 g
Fmoc-PNA-Maleimido Monomer

Catalog:FM-005

Formula:C26H25N3O7
Formula Weight:491.49
Fmoc-T-Aeg-OH
CAS:169396-92-3
Catalog:FM-006
PNA monomer incorporating a T nucleobase analogue through the Fmoc protecting group
Formula:C26H26N4O7
Formula Weight:506.51
Size:1 g/5 g/10 g/25 g
Fmoc-PNA-U-OH
CAS:959151-70-3
Catalog:FM-007
PNA monomer incorporating a U nucleobase analogue through the Fmoc protecting group
Formula:C25H24N4O5
Formula Weight:355.54
G-clamp PNA Monomers

Catalog:FM-008

Formula:C51H48N8O12
Formula Weight:964.97
Fmoc-Aeea-OH
CAS:166108-71-0
Catalog:FM-009

Formula:C21H23NO6
Formula Weight:385.4
Size:1 g
Fmoc-PNA-A(Boc)-OH
CAS:511534-99-9
Catalog:FM-010

Formula:C31H33N7O7
Formula Weight:615.65
Size:1 g/5 g
Fmoc-PNA-C(Boc)-OH
CAS:172405-61-7
Catalog:FM-011

Formula:C30H33N5O8
Formula Weight:591.62
Size:1 g/5 g
Fmoc-PNA-D(tetraBhoc)-OH

Catalog:FM-012

Formula:C82H66N8O13
Formula Weight:1371.47
Size:1 g/5 g
Fmoc-PNA-D(tetraBoc)-OH
CAS:2101661-88-3
Catalog:FM-013

Formula:C46H58N8O13
Formula Weight:931.01
Size:1 g/5 g/10 g/25 g
Fmoc-PNA-G(Boc)-OH
CAS:1052677-90-3
Catalog:FM-014

Formula:C31H33N7O8
Formula Weight:631.65
Size:1 g/5 g
Fmoc-PNA-J(Bhoc)-OH

Catalog:FM-015

Formula:C39H35N5O8
Formula Weight:701.74
Size:1 g/5 g
Fmoc-PNA-M(Bhoc)-OH

Catalog:FM-016

Formula:C40H36N4O7
Formula Weight:684.75
Size:1 g/5 g
Fmoc-PNA-M(Boc)-OH
CAS:1417611-27-8
Catalog:FM-017

Formula:C31H34N4O7
Formula Weight:574.63
Size:1 g/5 g

Introduction

PNA is an oligonucleotide analog prepared by conventional solid-phase peptide synthesis (SPPS) techniques. Solid-phase synthesis-based t-Boc and Fmoc schemes are widely used. The Fmoc solution enhances high-quality synthetic products while avoiding the use of highly corrosive chemicals. As a result, Fmoc SPPS has become a commercially popular synthesis technique. The Fmoc group is significantly selective for the protection of aliphatic primary amines of PNA monomers, but the protection of this group against the extra-cyclic amino groups of nucleobases A, C and G must be determined. The protecting group must provide sufficient protection during the synthesis process. In addition, it should be easily removed under dissociative conditions and must exhibit sufficient solubility for the corresponding monomers. Bhoc is the best candidate. It allows the PNA monomer to be preserved in 0.2 mol/L NMP for several weeks. Bhoc can be removed in less than a minute with clean TFA.

The labeling of PNA is accomplished with the linking of the cross-linker to the amino terminus. PNA can be labeled directly at the amino terminals. But often an arm is added between the reporter gene and the probe so as not to interfere with hybridization. The most commonly used arm is the 8-amino-3,6-dioxaoctanoic acid known as O-monomer. Fmoc-AEEA-OH is hydrophilic. It has the advantage of improving the yield of labeling reactions and increasing the solubility of PNA in aqueous solutions.

Fig. 1 Structure of Fmoc-AEEA-OH.Fig. 1 Structure of Fmoc-AEEA-OH.

Advantages of Our Products

  • High purity
  • High solubility
  • High reactivity
  • Reasonable price

Reference

  • Behrendt R; et al. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016 Jan; 22(1): 4-27.

For Research Use Only. Not For Clinical Use.